Actinium Pharmaceuticals (ATNM) Coverage Initiated at B. Riley
Analysts at B. Riley began coverage on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a report released on Wednesday. The brokerage set a “buy” rating and a $2.75 price target on the biotechnology company’s stock. B. Riley’s price objective would indicate a potential upside of 292.86% from the stock’s previous close.
A number of other research analysts have also recently issued reports on ATNM. Maxim Group reaffirmed a “buy” rating and set a $3.00 price objective on shares of Actinium Pharmaceuticals in a research note on Wednesday, October 25th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Finally, Roth Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) traded down $0.03 during midday trading on Wednesday, reaching $0.70. The company’s stock had a trading volume of 862,800 shares, compared to its average volume of 712,035. Actinium Pharmaceuticals has a twelve month low of $0.54 and a twelve month high of $1.72.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.